M Wang1, S Ji1, G Shao2, J Zhang3, K Zhao1, Z Wang1, A Wu4. 1. General Surgery Department, Zhujiang Hospital, Southern Medical University/The Second School of Clinical Medicine, Guangzhou, Guangdong, People's Republic of China. 2. Center of Special Medical Care, Zhujiang Hospital, Southern Medical University/The Second School of Clinical Medicine, Guangzhou, Guangdong, People's Republic of China. 3. Breast Surgery Department, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, People's Republic of China. 4. General Surgery Department, Zhujiang Hospital, Southern Medical University/The Second School of Clinical Medicine, Guangzhou, Guangdong, People's Republic of China. wagtyz@sina.com.
Abstract
PURPOSE: Exosomes are gradually detected as an indicator for diagnosis and prognosis of breast cancer in clinic and a systematic review was conducted. METHODS: A search for clinical studies published before July 1, 2017 was performed. Methods of exosome purification and identification from all studies were extracted. For diagnosis evaluation, the comparison of exosome biomarkers expression between breast cancer patients and healthy women was obtained; for prognosis prediction, the correlation between exosome biomarkers expression and chemotherapy resistance, overall survival (OS), disease-free survival (DFS), recurrence and metastasis of breast cancer was also extracted. RESULTS: A total of 11 studies with 921 breast cancer patients were included. Ultracentrifugation is the most frequent method to purify exosomes and transmission electron microscopy is commonly used to identify exosomes. Exosome biomarkers (such as HER2, CD47, Del-1, miR-1246 and miR-21) in breast cancer patients are significantly higher than those in healthy controls, exosomal GSTP1 and TRPC5 are related to chemotherapy resistance, exosome-carrying TRPC5, NANOG, NEUROD1, HTR7, KISS1R and HOXC are correlated to PFS, DFS or OS, and some exosomal proteins (HER2, KDR, CD49d, CXCR4 and CD44) as well as miRNAs (miR-340-5p, miR-17-5p, miR-130a-3p, miR-93-5p) are associated with tumor recurrence or distant organ metastasis. CONCLUSIONS: Exosome biomarkers can be used for early diagnosis and prognosis of breast cancer patients in clinic.
PURPOSE: Exosomes are gradually detected as an indicator for diagnosis and prognosis of breast cancer in clinic and a systematic review was conducted. METHODS: A search for clinical studies published before July 1, 2017 was performed. Methods of exosome purification and identification from all studies were extracted. For diagnosis evaluation, the comparison of exosome biomarkers expression between breast cancerpatients and healthy women was obtained; for prognosis prediction, the correlation between exosome biomarkers expression and chemotherapy resistance, overall survival (OS), disease-free survival (DFS), recurrence and metastasis of breast cancer was also extracted. RESULTS: A total of 11 studies with 921 breast cancerpatients were included. Ultracentrifugation is the most frequent method to purify exosomes and transmission electron microscopy is commonly used to identify exosomes. Exosome biomarkers (such as HER2, CD47, Del-1, miR-1246 and miR-21) in breast cancerpatients are significantly higher than those in healthy controls, exosomal GSTP1 and TRPC5 are related to chemotherapy resistance, exosome-carrying TRPC5, NANOG, NEUROD1, HTR7, KISS1R and HOXC are correlated to PFS, DFS or OS, and some exosomal proteins (HER2, KDR, CD49d, CXCR4 and CD44) as well as miRNAs (miR-340-5p, miR-17-5p, miR-130a-3p, miR-93-5p) are associated with tumor recurrence or distant organ metastasis. CONCLUSIONS: Exosome biomarkers can be used for early diagnosis and prognosis of breast cancerpatients in clinic.
Entities:
Keywords:
Breast cancer; Diagnosis; Exosome biomarkers; Prognosis
Authors: Bethany N Hannafon; Yvonne D Trigoso; Cameron L Calloway; Y Daniel Zhao; David H Lum; Alana L Welm; Zhizhuang J Zhao; Kenneth E Blick; William C Dooley; W Q Ding Journal: Breast Cancer Res Date: 2016-09-08 Impact factor: 6.466
Authors: Valeriy Domenyuk; Zhenyu Zhong; Adam Stark; Nianqing Xiao; Heather A O'Neill; Xixi Wei; Jie Wang; Teresa T Tinder; Sonal Tonapi; Janet Duncan; Tassilo Hornung; Andrew Hunter; Mark R Miglarese; Joachim Schorr; David D Halbert; John Quackenbush; George Poste; Donald A Berry; Günter Mayer; Michael Famulok; David Spetzler Journal: Sci Rep Date: 2017-02-20 Impact factor: 4.379
Authors: Lynn Chollet-Hinton; Carey K Anders; Chiu-Kit Tse; Mary Beth Bell; Yang Claire Yang; Lisa A Carey; Andrew F Olshan; Melissa A Troester Journal: Breast Cancer Res Date: 2016-08-04 Impact factor: 6.466